The coordinated effects of Apatinib and Tripterine on the proliferation, invasiveness and apoptosis of human hepatoma Hep3B cells

Li,Huihui; Fan,Yichang; Yang,Fan; Zhao,Lei; Cao,Bangwei

doi:10.3892/ol.2018.8656

The coordinated effects of Apatinib and Tripterine on the proliferation, invasiveness and apoptosis of human hepatoma Hep3B cells

Authors:
- Huihui Li
- Yichang Fan
- Fan Yang
- Lei Zhao
- Bangwei Cao
View Affiliations

Affiliations: Department of Cancer Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, P.R. China
Published online on: May 7, 2018 https://doi.org/10.3892/ol.2018.8656
Pages: 353-361
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

As a novel vascular endothelial growth factor receptor‑2 (VEGFR‑2) tyrosine kinase inhibitor, Apatinib has exhibited antitumor effects in a variety of solid tumors. Extracts of Chinese herbal medicines have emerged as a promising alternative option to increase the sensitivity of patients to chemotherapeutics while alleviating side effects. The present study aimed to investigate the effects of Apatinib and the traditional Chinese herb Tripterine on the proliferation, invasion and apoptosis of human hepatoma Hep3B cells. The expression of VEGFR‑2 in Hep3B cells was detected by western blotting and immunofluorescence assays. Hep3B cells were then divided into four different groups: Control group, Apatinib group, Tripterine group and Apatinib plus Tripterine group. The proliferation, invasion and apoptosis of these four groups of Hep3B cells were assessed by MTS, wound healing and Transwell assays, and flow cytometry, respectively. Finally, the levels of the proliferation‑associated proteins phosphorylated protein kinase B (p‑Akt) and phosphorylated extracellular signal‑regulated kinase (p‑ERK) and the apoptosis‑associated proteins cleaved Caspase‑3 and B‑cell lymphoma‑associated X protein (Bax) were detected by western blotting. The proliferation, migration and invasion of Hep3B cells were significantly inhibited by Apatinib and Tripterine, compared with the control group (P<0.01). The inhibitory effect of the combination group was markedly stronger than that of the Apatinib and Tripterine groups. The downregulation of p‑Akt and p‑ERK induced by Apatinib and Tripterine was further inhibited in the combination group (P<0.05), and the expression levels of Caspase‑3 and Bax were also significantly increased in the combination group (P<0.05). The combination of Apatinib and Tripterine significantly inhibited the proliferation, migration and invasion ability and promoted the apoptosis of Hep3B cells by downregulating the expression of p‑Akt and p‑ERK, and upregulating the expression of Caspase‑3 and Bax.

View Figures

View References

1	Torre LA, Sauer AM, Chen MS Jr, Kagawa-Singer M, Jemal A and Siegel RL: Cancer statistics for Asian Americans, native Hawaiians, and Pacific Islanders, 2016: Convergence of incidence between males and females. CA Cancer J Clin. 66:182–202. 2016. View Article : Google Scholar : PubMed/NCBI
2	Molina-Sánchez P and Lujambio A: Strategies for HCC target discovery. Aging (Albany NY). 9:1088–1089. 2017.PubMed/NCBI
3	Azumi M, Suda T, Terai S, Terai K and Akazawa K: Prognostic impact of indocyanine green plasma disappearance rate in hepatocellular carcinoma patients after radiofrequency ablation: A prognostic nomogram study. Intern Med. 56:1001–1007. 2017. View Article : Google Scholar : PubMed/NCBI
4	Yu SJ: A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010–2016. Clin Mol Hepatol. 22:7–17. 2016. View Article : Google Scholar : PubMed/NCBI
5	Lin J, Shen A, Chen H, Liao J, Xu T, Liu L, Lin J and Peng J: Nitidine chloride inhibits hepatic cancer growth via modulation of multiple signaling pathways. BMC Cancer. 14:7292017. View Article : Google Scholar
6	Liu Z, Wang T, Zhang Z, Tang S, Feng S, Yue M, Hu M, Xuan L and Chen Y: Survivin downregulation using siRNA nanoliposomes inhibits cell proliferation and promotes the apoptosis of MHCC-97H hepatic cancer cells: An in vitro and in vivo study. Oncol Lett. 13:2723–2730. 2017. View Article : Google Scholar : PubMed/NCBI
7	Kelley RK, Verslype C, Cohn AL, Yang TS, Su WC, Burris H, Braiteh F, Vogelzang N, Spira A, Foster P, et al: Cabozantinib in hepatocellular carcinoma: Results of a phase 2 placebo-controlled randomized discontinuation study. Ann Oncol. 28:528–534. 2017. View Article : Google Scholar : PubMed/NCBI
8	Al-Rajabi R, Patel S, Ketchum NS, Jaime NA, Lu TW, Pollock BH and Mahalingam D: Comparative dosing and efficacy of sorafenib in hepatocellular cancer patients with varying liver dysfunction. J Gastrointest Oncol. 6:259–267. 2017.
9	Peng S, Zhang Y, Peng H, Ke Z, Xu L, Su T, Tsung A, Tohme S, Huang H, Zhang Q, et al: Intracellular autocrine VEGF signaling promotes EBDC cell proliferation, which can be inhibited by Apatinib. Cancer Lett. 373:193–202. 2016. View Article : Google Scholar : PubMed/NCBI
10	Roviello G, Ravelli A, Polom K, Petrioli R, Marano L, Marrelli D, Roviello F and Generali D: Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer. Cancer Lett. 372:187–191. 2016. View Article : Google Scholar : PubMed/NCBI
11	Li F, Liao Z, Zhao J, Zhao G, Li X, Du X, Yang Y and Yang J: Efficacy and safety of Apatinib in stage IV sarcomas: Experience of a major sarcoma center in China. Oncotarget. 8:64471–64480. 2017.PubMed/NCBI
12	Li K and Li J: Current molecular targeted therapy in advanced gastric cancer: A comprehensive review of therapeutic mechanism, clinical trials, and practical application. Gastroenterol Res Pract. 2016:41056152016. View Article : Google Scholar : PubMed/NCBI
13	Zhang H: Apatinib for molecular targeted therapy in tumor. Drug Des Devel Ther. 9:6075–6081. 2015. View Article : Google Scholar : PubMed/NCBI
14	Hu X, Cao J, Hu W, Wu C, Pan Y, Cai L, Tong Z, Wang S, Li J, Wang Z, et al: Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer. BMC Cancer. 14:8202014. View Article : Google Scholar : PubMed/NCBI
15	Langer CJ, Mok T and Postmus PE: Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC). Cancer Treat Rev. 39:252–260. 2013. View Article : Google Scholar : PubMed/NCBI
16	Kou P, Zhang Y, Shao W, Zhu H, Zhang J, Wang H, Kong L and Yu J: Significant efficacy and well safety of apatinib in an advanced liver cancer patient: a case report and literature review. Oncotarget. 8:20510–20515. 2017. View Article : Google Scholar : PubMed/NCBI
17	Shrivastava S, Jeengar MK, Reddy VS, Reddy GB and Naidu VG: Anticancer effect of celastrol on human triple negative breast cancer: Possible involvement of oxidative stress, mitochondrial dysfunction, apoptosis and PI3K/Akt pathways. Exp Mol Pathol. 98:313–327. 2015. View Article : Google Scholar : PubMed/NCBI
18	Lee HW, Jang KS, Choi HJ, Jo A, Cheong JH and Chun KH: Celastrol inhibits gastric cancer growth by induction of apoptosis and autophagy. BMB Rep. 47:697–702. 2014. View Article : Google Scholar : PubMed/NCBI
19	Rajendran P, Li F, Shanmugam MK, Kannaiyan R, Goh JN, Wong KF, Wang W, Khin E, Tergaonkar V, Kumar AP, et al: Celastrol suppresses growth and Induces apoptosis of human hepatocellular carcinoma through the modulation of STAT3/JAK2 signaling cascade in vitro and in vivo. Cancer Prev Res. 5:631–643. 2012. View Article : Google Scholar
20	Li H, Li Y, Liu D, Sun H and Liu J: miR-224 is critical for celastrol-induced inhibition of migration and invasion of hepatocellular carcinoma cells. Cell Physiol Biochem. 32:448–458. 2013. View Article : Google Scholar : PubMed/NCBI
21	Chakravarthy R, Clemens MJ, Pirianov G, Perdios N, Mudan S, Cartwright JE and Elia A: Role of the eIF4E binding protein 4E-BP1 in regulation of the sensitivity of human pancreatic cancer cells to TRAIL and celastrol-induced apoptosis. Biol Cell. 105:414–429. 2013. View Article : Google Scholar : PubMed/NCBI
22	Yang S and Liu G: Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma. Oncol Lett. 13:1041–1047. 2017. View Article : Google Scholar : PubMed/NCBI
23	Popper HH: Progression and metastasis of lung cancer. Cancer Metastasis Rev. 35:75–91. 2016. View Article : Google Scholar : PubMed/NCBI
24	Arvelo F, Sojo F and Cotte C: Tumour progression and metastasis. Ecancermedicalscience. 10:6172016. View Article : Google Scholar : PubMed/NCBI
25	Vilanova G, Colominas I and Gomez H: A mathematical model of tumour angiogenesis: Growth, regression and regrowth. J R Soc Interface. 14:201609182017. View Article : Google Scholar : PubMed/NCBI
26	Fontanella C, Ongaro E, Bolzonello S, Guardascione M, Fasola G and Aprile G: Clinical advances in the development of novel VEGFR2 inhibitors. Ann Transl Med. 2:1232014.PubMed/NCBI
27	Bertino G, Demma S, Ardiri A, Proiti M, Gruttadauria S, Toro A, Malaguarnera G, Bertino N, Malaguarnera M, Malaguarnera M and Di Carlo I: Hepatocellular carcinoma: Novel molecular targets in carcinogenesis for future therapies. Biomed Res Int. 2014:2036932014. View Article : Google Scholar : PubMed/NCBI
28	Zhao Y and Adjei AA: Targeting angiogenesis in cancer therapy: Moving beyond vascular endothelial growth factor. Oncologist. 20:660–673. 2015. View Article : Google Scholar : PubMed/NCBI
29	Al-Abd AM, Alamoudi AJ, Abdel-Naim AB, Neamatallah TA and Ashour OM: Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies-A review. J Adv Res. 8:591–605. 2017. View Article : Google Scholar : PubMed/NCBI
30	Ding J, Chen X, Gao Z, Dai X, Li L, Xie C, Jiang H, Zhang L and Zhong D: Metabolism and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor apatinib in humans. Drug Metab Dispos. 41:1195–1210. 2013. View Article : Google Scholar : PubMed/NCBI
31	Schulte N, Ebert MP and Härtel N: Gastric cancer: New drugs-New strategies. Gastrointest Tumors. 1:180–194. 2014. View Article : Google Scholar : PubMed/NCBI
32	Li J, Qin S, Xu J, Guo W, Xiong J, Bai Y, Sun G, Yang Y, Wang L, Xu N, et al: Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: Results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol. 31:3219–3225. 2013. View Article : Google Scholar : PubMed/NCBI
33	Roviello G, Ravelli A, Fiaschi AI, Cappelletti MR, Gobbi A, Senti C, Zanotti L, Polom K, Reynolds AR, Fox SB and Generali D: Apatinib for the treatment of gastric cancer. Expert Rev Gastroenterol Hepatol. 10:887–892. 2016.PubMed/NCBI
34	Venkatesha SH and Moudgil KD: Celastrol and its role in controlling chronic diseases. Adv Exp Med Biol. 928:267–289. 2016. View Article : Google Scholar : PubMed/NCBI
35	Wang Z, Zhai Z and Du X: Celastrol inhibits migration and invasion through blocking the NF-κB pathway in ovarian cancer cells. Exp Ther Med. 14:819–824. 2017. View Article : Google Scholar : PubMed/NCBI
36	Figueiredo SAC, Salvador JAR, Cortés R and Cascante M: Novel celastrol derivatives with improved selectivity and enhanced antitumour activity: Design, synthesis and biological evaluation. Eur J Med Chem. 138:422–437. 2017. View Article : Google Scholar : PubMed/NCBI
37	Brahmbhatt H, Uehling D, Al-Awar R, Leber B and Andrews D: Small molecules reveal an alternative mechanism of Bax activation. Boichem J. 473:1073–1083. 2016. View Article : Google Scholar
38	Luna-Vargas MPA and Chipuk JE: Physiological and pharmacological control of BAK, BAX, and beyond.trends. Cell Biol. 26:906–917. 2016.
39	Todt F, Cakir Z, Reichenbach F, Emschermann F, Lauterwasser J, Kaiser A, Ichim G, Tait SW, Frank S, Langer HF and Edlich F: Differential retrotranslocation of mitochondrial Bax and Bak. EMBO J. 34:67–80. 2015. View Article : Google Scholar : PubMed/NCBI
40	Burgess JT, Bolderson E, Adams MN, Baird AM, Zhang SD, Gately KA, Umezawa K, O'Byrne KJ and Richard DJ: Activation and cleavage of SASH1 by caspase-3 mediates an apoptotic response. Cell Death Dis. 7:e24692016. View Article : Google Scholar : PubMed/NCBI
41	Kochetkova EY, Blinova GI, Bystrova OA, Martynova MG, Pospelov VA and Pospelova TV: Targeted elimination of senescent Ras-transformed cells by suppression of MEK/ERK pathway. Aging (Albany NY). 9:2352–2375. 2017.PubMed/NCBI
42	Adlung L, Kar S, Wagner MC, She B, Chakraborty S, Bao J, Lattermann S, Boerries M, Busch H, Wuchter P, et al: Protein abundance of AKT and ERK pathway components governs cell type-specific regulation of proliferation. Mol Syst Biol. 13:9042017. View Article : Google Scholar : PubMed/NCBI
43	Ewald F, Nörz D, Grottke A, Bach J, Herzberger C, Hofmann BT, Nashan B and Jücker M: Vertical targeting of AKT and mTOR as well as Dual targeting of AKT and MEK signaling is synergistic in hepatocellular carcinoma. J Cancer. 6:1195–1205. 2015. View Article : Google Scholar : PubMed/NCBI
44	Renault TT and Chipuk JE: Death upon a kiss: Mitochondrial outer membrane composition and organelle communication govern sensitivity to BAK/BAX-dependent apoptosis. Chem Biol. 21:114–123. 2014. View Article : Google Scholar : PubMed/NCBI
45	McIlwain DR, Berger T and Mak TW: Caspase functions in cell death and disease. Cold Spring Harb Perspect Biol. 7:a0086562013.
46	Wu W, Zhang D, Pan D, Zuo G, Ren X and Chen S: Downregulation of vascular endothelial growth factor receptor-2 under oxidative stress conditions is mediated by β-transduction repeat-containing protein via glycogen synthase kinase-3β signaling. Int J Mol Med. 37:911–920. 2016. View Article : Google Scholar : PubMed/NCBI